Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Brexit deal on medicines regulation must happen according to ABPI CEO

Brexit deal on medicines regulation must happen according to ABPI CEO

29th October 2018

Mike Thompson, CEO of the ABPI, has told MPs that pharmaceutical companies are increasing medicine stocks and duplicating testing in the EU, in order to limit supply disruption in the event of a no-deal Brexit, but there must be a deal in place to protect patients’ long term needs. He said some medicines “simply can’t be stockpiled due to temperature control, short shelf life or inability to travel. That is why we urgently need a deal. It is vital that both sides rapidly agree the terms of the UK’s withdrawal and a future relationship based on long-term cooperation on the regulation, trade and supply of medicines to protect public health, manage medicines safety and control infectious diseases throughout Europe.” He also pointed out that the UK needs a deal to maintain investment in UK clinical trials which benefit many patients and are profitable for the NHS.

In the event of a no-deal, the Medicines and Healthcare products Regulatory Agency would become the medicines and medical devices regulator, and would undertake the tasks and make the decisions that fall to the EU at the moment, for example marketing authorisation applications, paediatric investigation plans and orphan status, and pharmacovigilance responsibilities.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.